Defects in cell death signaling pathways acquired during the course of cancer progression provide cancer cells prominent survival edge amid oncogenic stress and chromosome instability. Furthermore, alteration of these pathways induces resistance to chemotherapeutic agents. Thus, modulation of apoptosis by targeting components of the apoptotic machinery and its regulators to restore apoptotic function is a rational approach for treating cancer. This talk summarizes our current research on BCL-2 protein family members, aiming to exploit cell death defects in cancer cells for more effective and selective cancer therapeutics.

Date-Time : Wednesday, November 11, 2015 – at 15:40
Place       : SBZ-14
Host        : Serkan Göktuna